James Aronson
Concepts (126)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteogenesis, Distraction | 14 | 2016 | 72 | 1.330 |
Why?
| Bone Regeneration | 6 | 2016 | 71 | 0.710 |
Why?
| Osteogenesis | 12 | 2012 | 377 | 0.660 |
Why?
| Tumor Necrosis Factor-alpha | 8 | 2013 | 435 | 0.490 |
Why?
| Ethanol | 8 | 2011 | 323 | 0.460 |
Why?
| Tibia | 10 | 2011 | 117 | 0.430 |
Why?
| Bone and Bones | 6 | 2020 | 516 | 0.350 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 5 | 2013 | 40 | 0.270 |
Why?
| Fibroblast Growth Factors | 1 | 2004 | 60 | 0.240 |
Why?
| Ulna | 1 | 2003 | 16 | 0.230 |
Why?
| Cisplatin | 2 | 2016 | 351 | 0.210 |
Why?
| Thiazolidinediones | 2 | 2012 | 95 | 0.210 |
Why?
| Diagnostic Imaging | 1 | 2003 | 185 | 0.200 |
Why?
| Osteogenesis Imperfecta | 1 | 2020 | 38 | 0.190 |
Why?
| Animals | 21 | 2016 | 14411 | 0.170 |
Why?
| Aging | 3 | 2010 | 784 | 0.150 |
Why?
| Interleukin-1 | 3 | 2005 | 107 | 0.140 |
Why?
| Mice, Inbred C57BL | 9 | 2016 | 2001 | 0.140 |
Why?
| Osteosarcoma | 1 | 2016 | 37 | 0.140 |
Why?
| Antineoplastic Agents | 2 | 2016 | 1300 | 0.140 |
Why?
| Piperazines | 1 | 2016 | 115 | 0.130 |
Why?
| Imidazoles | 1 | 2016 | 143 | 0.130 |
Why?
| Immunohistochemistry | 6 | 2012 | 1090 | 0.120 |
Why?
| Hypoglycemic Agents | 2 | 2012 | 177 | 0.120 |
Why?
| Adipocytes | 2 | 2012 | 128 | 0.120 |
Why?
| Bone Development | 2 | 2012 | 69 | 0.120 |
Why?
| Recombinant Proteins | 4 | 2010 | 570 | 0.120 |
Why?
| Mice | 11 | 2013 | 6429 | 0.110 |
Why?
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2010 | 16 | 0.110 |
Why?
| Alcoholism | 3 | 2005 | 249 | 0.110 |
Why?
| Signal Transduction | 4 | 2011 | 1754 | 0.110 |
Why?
| Choristoma | 1 | 2012 | 23 | 0.110 |
Why?
| Scoliosis | 1 | 2013 | 59 | 0.110 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2013 | 119 | 0.110 |
Why?
| Rats | 8 | 2007 | 3419 | 0.100 |
Why?
| Rats, Sprague-Dawley | 6 | 2005 | 1664 | 0.100 |
Why?
| Inhibins | 1 | 2011 | 20 | 0.100 |
Why?
| Bone Diseases | 1 | 2012 | 109 | 0.100 |
Why?
| Adipose Tissue | 1 | 2012 | 208 | 0.090 |
Why?
| Central Nervous System Depressants | 3 | 2007 | 78 | 0.090 |
Why?
| Osteoblasts | 2 | 2011 | 514 | 0.090 |
Why?
| Regeneration | 1 | 2010 | 72 | 0.090 |
Why?
| Bone Density | 3 | 2007 | 416 | 0.080 |
Why?
| Radiography | 4 | 2013 | 526 | 0.080 |
Why?
| Male | 14 | 2020 | 27348 | 0.080 |
Why?
| Injections, Intralesional | 1 | 2006 | 38 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 674 | 0.070 |
Why?
| Estrus | 1 | 2005 | 11 | 0.070 |
Why?
| Insulin-Like Growth Factor I | 1 | 2006 | 137 | 0.070 |
Why?
| Pregnancy, Animal | 1 | 2005 | 30 | 0.070 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2007 | 140 | 0.070 |
Why?
| Fracture Healing | 1 | 2004 | 26 | 0.060 |
Why?
| Mice, Knockout | 3 | 2013 | 927 | 0.060 |
Why?
| In Situ Hybridization | 1 | 2004 | 82 | 0.060 |
Why?
| Awards and Prizes | 1 | 2004 | 20 | 0.060 |
Why?
| Dogs | 1 | 2003 | 216 | 0.060 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2005 | 202 | 0.060 |
Why?
| Analysis of Variance | 1 | 2004 | 634 | 0.060 |
Why?
| Bone Resorption | 1 | 2005 | 328 | 0.060 |
Why?
| Parenteral Nutrition, Total | 1 | 2002 | 26 | 0.050 |
Why?
| Sialoglycoproteins | 1 | 2002 | 9 | 0.050 |
Why?
| Models, Animal | 3 | 2007 | 255 | 0.050 |
Why?
| 5' Untranslated Regions | 1 | 2020 | 33 | 0.050 |
Why?
| Pregnancy Complications | 1 | 2005 | 387 | 0.050 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2007 | 486 | 0.050 |
Why?
| Cell Division | 3 | 2005 | 330 | 0.040 |
Why?
| Membrane Proteins | 1 | 2020 | 389 | 0.040 |
Why?
| Tomography, X-Ray Computed | 3 | 2012 | 1222 | 0.040 |
Why?
| Young Adult | 2 | 2020 | 4319 | 0.040 |
Why?
| Osteotomy | 2 | 2007 | 35 | 0.040 |
Why?
| Humans | 6 | 2020 | 54397 | 0.030 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2016 | 220 | 0.030 |
Why?
| Mice, Nude | 1 | 2016 | 284 | 0.030 |
Why?
| Random Allocation | 1 | 2016 | 312 | 0.030 |
Why?
| Cell Proliferation | 2 | 2011 | 1097 | 0.030 |
Why?
| Child | 2 | 2020 | 7368 | 0.030 |
Why?
| Mutation | 1 | 2020 | 1504 | 0.030 |
Why?
| Proliferating Cell Nuclear Antigen | 2 | 2003 | 82 | 0.030 |
Why?
| Models, Biological | 2 | 2007 | 825 | 0.030 |
Why?
| Observer Variation | 1 | 2013 | 139 | 0.030 |
Why?
| Female | 4 | 2020 | 28474 | 0.030 |
Why?
| X-Ray Microtomography | 1 | 2012 | 82 | 0.030 |
Why?
| Treatment Outcome | 1 | 2003 | 5612 | 0.030 |
Why?
| Infant | 1 | 2020 | 3830 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2012 | 158 | 0.030 |
Why?
| RNA, Messenger | 2 | 2007 | 1203 | 0.030 |
Why?
| Tibial Fractures | 1 | 2011 | 34 | 0.030 |
Why?
| Down-Regulation | 1 | 2012 | 388 | 0.020 |
Why?
| Solubility | 1 | 2010 | 75 | 0.020 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 93 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2011 | 658 | 0.020 |
Why?
| Staining and Labeling | 1 | 2009 | 106 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1301 | 0.020 |
Why?
| Blotting, Western | 1 | 2010 | 684 | 0.020 |
Why?
| Wound Healing | 1 | 2010 | 228 | 0.020 |
Why?
| TNF Receptor-Associated Factor 1 | 1 | 2007 | 3 | 0.020 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 36 | 0.020 |
Why?
| Rats, Zucker | 1 | 2007 | 74 | 0.020 |
Why?
| Electron Probe Microanalysis | 1 | 2006 | 8 | 0.020 |
Why?
| Cytochrome P-450 CYP2E1 | 1 | 2007 | 105 | 0.020 |
Why?
| Cytokines | 1 | 2010 | 677 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2006 | 174 | 0.020 |
Why?
| Time Factors | 1 | 2013 | 3210 | 0.020 |
Why?
| Chondrocytes | 1 | 2005 | 37 | 0.020 |
Why?
| Osteocalcin | 1 | 2005 | 46 | 0.020 |
Why?
| Mice, Inbred NOD | 1 | 2005 | 99 | 0.020 |
Why?
| Receptor, Insulin | 1 | 2005 | 44 | 0.020 |
Why?
| Interleukin-6 | 1 | 2007 | 315 | 0.020 |
Why?
| Middle Aged | 1 | 2020 | 13083 | 0.020 |
Why?
| Bony Callus | 1 | 2004 | 4 | 0.020 |
Why?
| Collagen Type I | 1 | 2005 | 97 | 0.020 |
Why?
| Bone Marrow | 1 | 2007 | 414 | 0.020 |
Why?
| Adult | 1 | 2020 | 14210 | 0.020 |
Why?
| Collagen | 1 | 2005 | 223 | 0.020 |
Why?
| Peptides | 1 | 2005 | 276 | 0.020 |
Why?
| Weight Gain | 1 | 2004 | 244 | 0.010 |
Why?
| Femur | 1 | 2003 | 144 | 0.010 |
Why?
| Insulin | 1 | 2005 | 511 | 0.010 |
Why?
| Osteopontin | 1 | 2002 | 16 | 0.010 |
Why?
| Intubation, Gastrointestinal | 1 | 2002 | 27 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2005 | 1477 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2002 | 401 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 6901 | 0.010 |
Why?
| Cell Line | 1 | 2003 | 1152 | 0.010 |
Why?
| Pregnancy | 1 | 2005 | 2641 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2002 | 1648 | 0.010 |
Why?
|
|
Aronson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|